264 results about "Cell subpopulations" patented technology

Methods of deconvolving a feature profile of a physical system are provided herein. The present method may include: optimizing a regression between a) a feature profile of a first plurality of distinct components and b) a reference matrix of feature signatures for a second plurality of distinct components, wherein the feature profile is modeled as a linear combination of the reference matrix, and wherein the optimizing includes solving a set of regression coefficients of the regression, wherein the solution minimizes 1) a linear loss function and 2) an L2-norm penalty function; and estimating the fractional representation of one or more distinct components among the second plurality of distinct components present in the sample based on the set of regression coefficients. Systems and computer readable media for performing the subject methods are also provided.

The invention discloses a treatment response prediction method and system, a storage medium and a terminal, and the method comprises the steps: carrying out the heterogeneity analysis and cell division of first single cell sequencing data of a patient through employing a clustering algorithm, and obtaining a plurality of corresponding cell subgroups; performing feature extraction and biomarker recognition on all the cell subgroups to obtain corresponding cell subgroup features; wherein the cell subset characteristics comprise a cell development trajectory and a plurality of cell markers; and inputting the clinical information and the cell subset characteristics of the patient into the treatment response prediction model, so that the model performs multi-factor analysis and outputs a treatment response prediction result of the patient for each treatment scheme. By adopting the embodiment of the invention, the tiny key difference between the cells is captured, the cells are divided based on the difference between the cells, and then feature extraction and biomarker recognition are performed on each cell subset, so that the specific gene expression modes of different cell subpopulations corresponding to diseases can be recognized, and the treatment response prediction accuracy is further improved.

The invention provides human placenta-derived vasogenic stem cells (hPASCs) and application thereof. The human placenta-derived angiogenic stem cells (hPASCs) disclosed by the invention are preserved in China Center for Type Culture Collection, Wuhan University, Wuhan, China; the preservation date is April 2, 2025; the preservation number of the strain is CCTCC (China Center For Type Culture Collection) NO: The hPASCs disclosed by the invention contain angiogenic cell subgroups, have stem cell stemness, have an angiogenesis effect in vivo and in vitro, and can be used for treatment of diseases such as cardiovascular diseases and vascularization construction of artificial organs and tissues.

The invention provides a kit for detecting spermatogenic ability of azoospermia patients and application thereof, and belongs to the technical field of reproductive medicines.The kit comprises the following reagents: testis tissue digestive juice and testis single cell flow staining fluid; the testis single cell flow type staining solution comprises a DNA (Deoxyribose Nucleic Acid) staining solution Hoechst 33342 and an RNA (Ribonucleic Acid) staining solution # imgabs0 # RNASelectTM green fluorescent cell staining agent; according to the kit, double staining of DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) is carried out on testis single cells, and a fluorescence activated cell sorting technique is matched, so that refining of testis single cell subgroups of azoospermia patients is realized, and the spermatogenic ability of the azoospermia patients is determined according to a testis single cell subgroup subdivision result. The kit disclosed by the invention is used for pre-operation evaluation of a microscopic sperm extraction operation, is used for judging whether a patient has spermatogenic ability and is suitable for microscopic sperm extraction or not, can also be used for guiding the patient to further clarify the cause of disease, and has important clinical significance.

The invention discloses an application of a polysaccharide monomer separated from schisandra chinensis in preparation of a PD-L1 + TAMs activator. A large number of experiments show that the polysaccharide monomer schisanan B separated from schisandra chinensis can effectively activate PD-L1 + TAMs cell subsets, so that the phagocytosis of TAMs is enhanced, and the proliferation of tumor cells is inhibited; therefore, it is determined that the polysaccharide monomer schisanan B separated from schisandra chinensis can serve as a natural PD-L1 + TAMs cell subset activator to be used for treating cancers such as non-small cell lung cancer, intestinal cancer, melanoma, urothelial carcinoma or liver cancer, and the polysaccharide monomer schisanan B has the advantages of being free of toxic and side effects, low in price, wide in adaptive patient population and the like.

The invention discloses an experimental method based on depletion-type nk cells as a lung cancer treatment target, and relates to the technical field of bioinformatics. Comprising the following steps: S1, data processing; s2, identification of cell subset characteristic genes and cell type annotation; s3, re-clustering the NK cells; s4, NK cell function annotation; s5, differential gene expression analysis; s6, analyzing the difference of activation and inhibition of receptor expression by the RGS1 + NK cells through single cells; s7, performing quasi-time sequence analysis; s8, carrying out cell culture and siRNA transfection; s9, detecting the expression condition of an NK92mi cell activated receptor after the RGS1 is knocked down; s10, carrying out a lactic dehydrogenase release experiment; s11, measuring the IFN-gamma content of the cell supernatant; and S12, virtual screening of drugs. Through analysis and experimental verification, the key function of RGS1 in NK cell depletion in lung cancer is disclosed, and a new and potential molecular target is provided for lung cancer treatment.

The invention discloses an scRNA-seq missing data prediction method based on depth map contrast learning. The scRNA-seq missing data prediction method comprises the following steps: 1, acquiring an scRNA-seq data matrix; 2, the scRNA-seq matrix is preprocessed; and 3, constructing a cell map by using the preprocessed scRNA-seq data. And 4, inputting the cell map data into a contrast learning module, and learning and obtaining the embedded representation of the cells. And 5, determining a neighbor cell of each cell based on the cell embedding representation, calculating a related weight of the neighbor cell and the neighbor cell through a least square method, and finally filling a missing value of each cell. And 6, evaluating the accuracy of the predicted value through downstream analysis. According to the method, the missing value can be well recovered, the clustering of the cell subpopulation is promoted, and the deduction of the cell development trajectory is facilitated.

The present invention relates to methods and products for assessing autophagic flux, and more specifically provides a biochemical functional measure used to quantify autophagic flux in sub-populations of blood cells. The present invention also provides lysosomal system markers for use in the methods described herein, systems for assessing autophagic flux, methods of identifying markers indicative of autophagic flux, and methods of treating subjects found to be suffering from, or susceptible to, a disease, condition or state associated with autophagic flux dysfunction using the methods described herein.

The invention discloses an application of a marker combination in prediction or diagnosis of gout, the marker combination comprises an immune cell subset and clinical data, and the immune cell subset comprises virus-specific cytotoxic NK cells and inhibitory Vdelta2 cells. The marker combination comprises immune cell subgroups and clinical data, different immune cell subgroups are matched with different clinical data when a gout attack stage and a gout remission stage are distinguished, or when the gout remission stage and a healthy subject are distinguished, and high-sensitivity and high-specificity diagnosis results are achieved. Therefore, the marker combination disclosed by the invention has a wide prospect in the aspect of predicting different processes of gout, and can provide more basic research data for health management of gout high-risk people.

The invention provides a method and system for analyzing lung cancer brain metastasis organoid cell subpopulation and functional characteristics, and the method comprises a series of steps: data quality control, batch effect removal, cell grouping, copy number variation inference, quasi-time sequence analysis, function enrichment analysis, and drug sensitivity analysis before and after radiotherapy. Single cell transcriptome sequencing data obtained after organoid culture is subjected to personalized analysis, heterogeneity of tumor cells and sensitivity of the tumor cells to drugs after radiotherapy are described, and the characteristics of all cell subgroups in the lung cancer brain metastasis organoid and the effect of the cell subgroups in the tumor microenvironment can be accurately analyzed; powerful support is provided for mechanism research and precise medicine of lung cancer brain metastasis.

The invention provides a new bunyavirus neutralizing antibody screening method based on single cell BCR sequencing. The new bunyavirus neutralizing antibody screening method comprises the following steps: S1, collecting peripheral blood B cells of acute stage and recovery stage patients and healthy volunteers of new bunyavirus infected persons; s2, carrying out CD19 < + > CD38 < + > CD138 < + > magnetic bead separation to obtain a single-cell suspension; s3, constructing a single cell transcriptome and a BCR library, separating single cells by using a microfluidic system, and performing high-throughput sequencing; s4, analyzing a B cell subset, a BCR cloning amplification mode and a VJ gene pair enrichment characteristic through bioinformatics analysis; and S5, screening a specific BCR clone type related to the severity of the disease as a neutralizing antibody candidate target. The method provided by the invention provides powerful support for immune monitoring and vaccine design of new bunyavirus infection, and is expected to provide new strategies and methods for clinical treatment and prevention.

The invention discloses a giant salamander immune regulation meat peptide and application thereof. The meat peptide comprises one or more than two polypeptides selected from SEQ ID NOs: 1-5. The polypeptide can enhance cellular immune response, such as enhancing macrophage proliferation activity, improving macrophage nitric oxide secretion level, enhancing macrophage phagocytic ability, enhancing macrophage antigen presentation ability, enhancing immune organ functions, regulating T cell subpopulation, improving cellular immune factor level and enhancing immune globulin level.

The invention discloses a method for annotating a vesicle cell subset based on monovesicle membrane proteomics, and belongs to the technical field of vesicle cell annotation. The method comprises the following steps: 1, carrying out exosome collection on a plasma sample to obtain a sample; 2, coding and labeling the antibody probe, and adding a protein tag and a labeled DNA sequence into the antibody probe to obtain a labeled antibody probe; 3, preparing a corresponding combined product; 4, adding a labeled antibody probe into the sample to obtain an exosome compound; step 5, capturing an exosome conjugate through CTB; 6, adding the binding product into the exosome conjugate to generate a sequence; 7, constructing a sequence library and sequencing to obtain a sequencing sequence; 8, removing a sequencing sequence with low expression quantity to obtain an exosome expression data matrix, and standardizing the exosome expression data matrix; 9, carrying out clustering analysis to find out an exosome core subgroup; and step 10, determining the source of the exosome core subgroup, and annotating the single vesicle subgroup.

The invention belongs to the technical field of cell biology, and particularly relates to a preparation method of tumor enhanced targeting and therapeutic function extracellular vesicles and a chip device. The invention firstly provides an integrated chip device which is provided with a cell screening module and a functional preparation module and comprises a plurality of functional layers, wherein one functional layer is provided with a cell evolution screening area with gradient for cell screening, and the other functional layer is provided with a cell electric remodeling area for cell functionalization transformation. The invention innovatively proposes that tumor cells with strong metastasis ability are screened based on culture gradient, the tumor cells with stronger invasion ability are distinguished by utilizing spatial segmentation, then the screened cell subpopulation is transferred to a cell electric remodeling area in combination with overturning operation of the chip, and the cell subpopulation is transferred to the cell electric remodeling area in a manner of focusing an electric field through nanopores. And meanwhile, therapeutic molecules are efficiently delivered to realize cell transformation, so that the transformed cells can enhance the output of extracellular vesicles with a therapeutic function.

The invention discloses a screening method of sicca syndrome markers based on conjunctival blotting, and relates to the technical field of biomedicine, and the screening method comprises the following steps: S1, conjunctival noninvasive sampling; s2, RNA (Ribonucleic Acid) sequencing and pathway screening; s3, machine learning modeling is carried out; s4, clinical verification. According to the invention, biomarker screening is realized, and similar biomarker screening can also be realized through tear sample analysis or other ophthalmic samples; however, the alternative schemes have the defects of relatively strong invasiveness, complex operation and the like; sampling is carried out through the conjunctival imprinting technology, invasive operation such as biopsy and blood drawing is avoided, and pain and discomfort are reduced; differential expression genes can be accurately identified, and the sensitivity and the accuracy are relatively high; through immune cell infiltration analysis, the relationship between the immune cell subpopulation and the sicca syndrome related gene is disclosed, a new perspective is provided for a disease mechanism, and a theoretical basis is provided for a future immune regulation strategy.

The invention provides a single-cell multi-omics data clustering method based on a diffusion auto-encoder, and belongs to the technical field of biological single-cell data classification. Comprising the following steps: carrying out dimension reduction processing on paired single-cell omics A and omics B data to obtain two types of omics data with consistent dimensions; integrating the features of the two types of omics data by using a feature fusion module based on a bidirectional cross attention mechanism to obtain common semantic embedding z of the cells; generating random encoder features based on the two types of omics data, and reconstructing original data based on z and the random encoder features by using two conditional diffusion models; updating parameters of the conditional diffusion model by using a loss function to obtain a common semantic embedding z'which minimizes the loss function; and dividing the cells into different cell subgroups by using z'by using a clustering algorithm. According to the method, the semantic features and random noise of the cells are separated by using decoupling learning, and the cells are clustered by using cross-omics invariant features, so that different subtypes can be accurately identified.

The invention provides a dynamic regulation and control method for optimizing CAR-T cell amplification conditions, which comprises the following steps: acquiring high-frequency cell activity monitoring data from a cell culture system, and extracting metabolic marker fluctuation and proliferation rate mutation from the high-frequency cell activity monitoring data to obtain real-time cell state parameters; comparing the real-time cell state parameters with a T cell subset proportion and a cell factor release mode in historical immune data of the patient to obtain a cell state deviation value, and determining an abnormal fluctuation condition of proliferation rate mutation according to the cell state deviation value; if the abnormal fluctuation of the proliferation rate mutation exceeds a preset fluctuation threshold value, capturing proliferation signal abnormity by analyzing metabolic marker fluctuation and metabolic waste accumulation according to the cell state deviation value; according to the targeted culture parameter set, adjusting the oxygen supply quantity and the culture solution microenvironment of an oxygen concentration control system to obtain a culture environment for inhibiting cytokine storm and proliferation signal abnormity.

The invention discloses a progressive multiple sclerosis differential diagnosis marker based on immunophenomics and application of the progressive multiple sclerosis differential diagnosis marker. The invention specifically provides an immune biomarker set for identifying progressive or recurrent remission type multiple sclerosis and a corresponding reagent and kit thereof. The immune biological marker provided by the invention comprises one or more of the following groups: a) activating a T cell subset; b) a CD28 < + > and CD28-T cell subset; c) forming a subgroup by the CD8 + T cells; and d) a MAIT cell subset category. The immune biomarker disclosed by the invention can also be applied in a multi-index combination manner, and can be applied to a) multiple sclerosis patients which are not subjected to disease modification treatment; b) a patient with multiple sclerosis treated by disease modification; and c) a very good effect of distinguishing clinical subtypes of the multiple sclerosis can be achieved in the three types of people of the multiple sclerosis patients who do not distinguish whether the multiple sclerosis patients are subjected to the disease modification treatment or not.

The present invention belongs to the field of biological detection technology, and specifically relates to a prediction model for predicting the prognosis of non-small cell lung cancer (NSCLC) after neoadjuvant immunotherapy through metastatic lymph nodes (mLN) and a construction method thereof. The present invention uses a variety of spatial high-throughput sequencing bioinformatics technologies to analyze the key immune cell subsets, immune microenvironment topological characteristic structures and tertiary lymphoid body-related functional cell subsets of mLN after neoadjuvant immunotherapy. The proposed prediction model for predicting the prognosis of NSCLC after neoadjuvant immunotherapy through metastatic lymph nodes and its construction method are more in line with the changes in spatial histological characteristics of the immune microenvironment after treatment. Compared with the previous transcriptome sequencing method without spatial information, it more accurately characterizes the changes in the spatial tumor immune microenvironment after immunotherapy, and can more accurately predict the prognosis of NSCLC after neoadjuvant immunotherapy through cell targets that truly affect the efficacy of immunity.

The invention discloses application of T cell subgroups in preparation of a kit for evaluating B cell depletion therapy and application of the T cell subgroups in preparation of the kit for evaluating B cell depletion therapy, the T cell subgroups comprise one or more of CD4 + TCM, CD4 + TEM, CD8 + TCM, CD8 + TEM, CD20 dimCD4 + TCM, CD20 dimCD4 + TCM, CD20 dimCD8 + TEM, Th17.1, Th17, Th2, CD4 + TCMTh17.1, CD4 + TEMTh17 and CD4 + TEMTh2, and the T cell subgroups comprise one or more of CD4 + TCMTh17, CD4 + TEMTh17 and CD4 + TEMTh2.

To provide a cell proliferation system, proliferation method, control method, and culture medium bag capable of proliferating various adherent cells and suspension cells. [Solution] Cells are grown in a bioreactor and activated by an activator (e.g., a soluble activator complex). The nutrient supply and gas exchange functions of an automated closed cell proliferation system make it possible to seed at, for example, a low seeding density. By manipulating the parameters of the cell growth environment, cells are placed in specific locations within the bioreactor for efficient exchange of nutrients and gases. System parameters are adjusted to shear any cell colonies that may form during the proliferation phase. Metabolic concentrations are controlled to improve cell growth and viability. Cell retention within the bioreactor is controlled. In some embodiments, the cells include T cells. In other embodiments, the cells include a T cell subpopulation, for example, regulatory T cells (Tregs).

The present application relates to the technical field of bioinformatics, and particularly relates to a method for constructing a biological age prediction model based on DNA methylation. The method comprises the following steps: obtaining whole genome methylation sequencing data of a human peripheral blood sample; classifying cell subpopulations of the human peripheral blood sample, and performing single-cell RNA sequencing processing on each cell subpopulation to obtain single-cell sequencing data including lymphocytes, neutrophils and monocytes; performing tissue-specific analysis on CpG sites within a range of 2000 base pairs upstream and downstream of each cell subpopulation-specific transcription factor binding site according to the single-cell sequencing data and the whole genome methylation sequencing data to obtain candidate marker site data. The present application can provide strong support for early detection of accelerated aging, prediction of related disease risks and guidance of precision medicine.

The invention provides a lung adenocarcinoma immune cell subset network marker screening method. According to the lung adenocarcinoma immune cell subset network marker screening method, a lung adenocarcinoma immune cell subset network marker screening model with specificity and accuracy is constructed, and a network marker capable of accurately representing immune cell subset characteristics is screened out; meanwhile, by establishing a high-interpretability cell classification model based on the network markers and adopting the relevance between the network markers and cell classification results, the cell classification performance is improved, and effective and reliable verification of the network markers is achieved. Finally, a lung adenocarcinoma immune cell subset spatial relationship analysis algorithm based on the network marker regulatory relationship is constructed, the limitation of a high-cost spatial imaging technology is broken through, the correlation between the regulatory relationship between the network markers and immune cell spatial distribution is disclosed, and clues are provided for understanding a cell interaction mechanism in a tumor microenvironment.

Methods are disclosed for adding adapters to fragmented nucleic acids for next generation sequencing, including providing numerical codes based on variable adapter molecular barcode lengths on both sides of the fragmented nucleic acids and identifying reads from the same fragment based on both barcodes. The methods and products allow for the amplification of the fragmented nucleic acids when there is a low yield of isolated fragmented nucleic acids and also for efficient and reliable detection of low-frequency mutations including in subpopulations of cells within a subject.

The invention discloses a preparation method of a silicon dioxide nano vaccine for mediating constant natural killer T (iNKT) cells and application of the silicon dioxide nano vaccine in the field of tumor immunotherapy. The iNKT cell is a special T cell subset which can be activated by a glycolipid antigen presented by CD1d, and can directly kill tumor cells and activate other immune cells. Clinically, the classical agonist alpha GC of the iNKT cell can lead to function depletion of the iNKT cell after multiple intravenous administration, and finally evolves into an inactive state. Although the CD1d / alpha GC protein complex relieves the iNKT cell anenergetic state to a certain extent, the CD1d / alpha GC protein complex is easily degraded and cleared in a complex physiological environment, and the treatment effect is weakened. The characteristics of large aperture and high specific surface area of dendritic mesoporous silica are utilized, CD1d / alpha GC is loaded into a pore channel of a mesoporous nano-material, and the design can protect protein drugs from being degraded in blood circulation, so that a nano-vaccine capable of effectively mediating iNKT cells and successfully relieving the inability of the iNKT cells is constructed; and the effectiveness of the compound in tumor treatment is verified. The patent is supported by the national natural science fund (82001958).

The invention provides a universal UCMSC and a construction method and application thereof.The construction method includes the steps that a UCMSC specific lipid mixture containing ionizable lipid, auxiliary lipid, a stabilizer and cholesterol is prepared, the UCMSC specific lipid mixture is mixed with a nucleic acid solution containing CRISPRoff mRNA and a targeted B2M gene super enhancer sgRNA, and UCMSC specific LNP is prepared; the optimal universal UCMSC disclosed by the invention is constructed by transfecting P0-generation UCMSC with UCMSC specific LNP and screening a cell subset with low expression of HLA-I, the problems that existing universal cell construction depends on a virus or an electrotransfection system and genome change and immunological rejection exist are solved, and the optimal universal UCMSC has the effects of continuously and stably low immunogenicity, effectively avoiding immunological rejection and being free of permanent genome change. The construction method provided by the invention is safe and reliable, is simple and convenient to operate, improves the clinical accessibility of UCMSC cell therapy, reduces the burden of patients, and has a wide application prospect.

The invention belongs to the field of immunotoxicology, and particularly relates to a method for immunotyping bone marrow cells by flow cytometry. The flow cytometry immune typing method for bone marrow cells comprises the following steps: collecting macaca fascicularis bone marrow fluid, and preparing the macaca fascicularis bone marrow fluid into single-cell suspension; dyeing the obtained cells by using an antibody combination containing a plurality of fluorescent labels; then, a flow cytometer is used for collecting cell fluorescence signals, a standardized gate setting strategy is executed, and based on collected data, the percentage of each cell subset in CD45 + living white blood cells is calculated to complete immune typing. According to the flow cytometry immune typing method for the bone marrow cells, the problems of low efficiency, low repeatability, low sensitivity and poor specificity of related technologies are solved, and more accurate and reliable data support is provided for early discovery, risk assessment and mechanism research of drug immunotoxicity.

The invention discloses a method and a system for analyzing immune cell change of an HER2 variant lung cancer patient. The method comprises the following steps: collecting a peripheral blood sample and carrying out single-cell RNA (Ribonucleic Acid) sequencing; performing quality control, standardization processing, dimensionality reduction and clustering analysis on the sequencing data; carrying out immune cell subset annotation on the clustering result based on a preset immune cell marker; analyzing cell communication modes among different immune cell subpopulations by using a ligand-receptor database; performing quantitative statistics on the proportion of various immune cells based on sample grouping; and further performing subpopulation fine analysis, quasi-time sequence trajectory reconstruction and metabolic pathway activity evaluation on the CD8 + T cells to construct a comprehensive immune cell map. According to the method, the multi-dimensional characteristics of the peripheral blood immune cells can be presented at high resolution, and the comprehensive analysis of the functional state, the communication network and the metabolic activity of the immune cells is realized. According to the system and the device, automatic operation and visual display of the method can be realized. According to the invention, the immune monitoring efficiency can be improved, and an effective tool is provided for immune treatment effect evaluation and disease mechanism research.

A cancer immunotherapy for treating cancers such as melanoma is presented. A method for treating cancer in a subject via administration of anti-LY6E antibody to the subject. The method can further include administering an IFNAR blockade to inhibit type-1 interferon (IFN) signaling, thereby enhancing the ant-tumoral cytotoxic activity of T cells. The IFNAR can include anti-IFNα. The method can also include administering anti-PD1 antibody prior to, commensurate, or after treatment with anti-LY6E. A composition for treating cancer and modulating immune responses in a subject is also included. The composition can include, among other things, the anti-LY6E antibody, the IFNAR blockade, and anti-PD1. The composition and method also present a mechanism to modulate immune response in a subject by preventing upregulation of a Ly6ahigh T-cell subpopulation in response to a stimulus such as cancer, UVB, or interferons.

The invention discloses a single cell data expression profile reconstruction method based on a cell-gene heterogeneous bipartite graph and related equipment, and belongs to the technical field of bioinformation.The method comprises the steps that the cell-gene heterogeneous bipartite graph is constructed, and embedding of different types of gene nodes and cell nodes is updated through a graph neural network encoder; obtaining an initial cell node representation and an initial gene node representation; constructing global representation of two types of nodes on the whole graph and local representation of nodes on a closed sub-graph based on initial cell node representation and initial gene node representation, inputting the global representation and the local representation into a noise contrast loss function, scoring through a discriminator, obtaining cell node embedding and gene node embedding, and inputting the cell node embedding and the gene node embedding into a matrix decomposition model; and after an objective function is optimized, outputting a reconstructed single cell data expression profile. The method can solve the problem that in the prior art, more original information cannot be reserved when a single cell data expression profile is reconstructed, so that the cell subpopulation cannot be accurately recognized and the cell state cannot be reflected.